Structural Basis of Substrate Recognition and Covalent Inhibition of Cdu1 from Chlamydia trachomatis. (6th September 2018)

• Record Type: Journal Article
• Authors: Ramirez, Yesid A.; Adler, Thomas B.; Altmann, Eva; Klemm, Theresa; Tiesmeyer, Christian; Sauer, Florian; Kathman, Stefan G.; Statsyuk, Alexander V.; Sotriffer, Christoph; Kisker, Caroline
• Is Part Of: ChemMedChem. Volume 13:Number 19(2018)
• Page Start: 2014
• Page End: 2023
• Publication Date: 2018-09-06
• Subjects: CE proteases -- cyanopyrimidines -- deubiquitylating enzyme inhibition -- reversible covalent inhibitors -- target hopping; Pharmaceutical chemistry -- Periodicals; 615.19005
• DOI: 10.1002/cmdc.201800364
• Languages: English
• ISSNs: 1860-7179

Abstract

Abstract: Based on the similarity between the active sites of the deubiquitylating and deneddylating enzyme ChlaDub1 (Cdu1) and the evolutionarily related protease adenain, a target‐hopping screening approach on a focused set of adenain inhibitors was investigated. The cyanopyrimidine‐based inhibitors identified represent the first active‐site‐directed small‐molecule inhibitors of Cdu1. High‐resolution crystal structures of Cdu1 in complex with two covalently bound cyanopyrimidines, as well as with its substrate ubiquitin, were obtained. These structural data were complemented by enzymatic assays and covalent docking studies to provide insight into the substrate recognition of Cdu1, active‐site pocket flexibility and potential hotspots for ligand interaction. Combined, these data provide a strong basis for future structure‐guided medicinal chemistry optimization of this cyanopyrimidine scaffold into more potent and selective Cdu1 inhibitors. Abstract : Covalent targeting : Deubiquitylating enzymes are used by bacteria to enhance their pathogenicity. The structural similarities between the active sites of the chlamydial deubiquitylase 1 (Cdu1) and the evolutionarily related protease adenain were harnessed to discover the first covalent inhibitors of Cdu1. The molecular basis of ubiquitin recognition by Cdu1 is demonstrated, and criteria for the structure‐informed optimization of potential Cdu1‐specific inhibitors are established.